PreclinicalPh 1Ph 1/2Ph 2Ph 3
bluedotbluedotbluedotbluedotbluedotbluedot
CANCER VACCINES 
PROSTVAC®     
CV-301 breast     
CV-301 lung     
CV-301 ovarian     
MVA-BN® PRO     
MVA-BN® HER2     
 
INFECTIOUS DISEASES 
IMVAMUNE® liquid-frozen     
IMVAMUNE® freeze-dried     
MVA-BN® Anthrax     
MVA-BN® Filo     
MVA-BN® FMDV     
MVA-BN® RSV     

 

Our pipeline includes cancer immunotherapy candidates in major cancers and prophylactic vaccine candidates for bioterror agents and other infectious diseases.

PIPELINE

Cancer

The cancer pipeline is focused on therapeutic cancer vaccines. The lead program is PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed in collaboration with the National Cancer Institute.

Infectious diseases

The infectious disease pipeline is focused on preventive vaccines for biodefense under fully funded government programs and commercial targets. The lead biodefense program is IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 trials, which is being developed and supplied for emergency use to the U.S. Strategic  National Stockpile under a contract with the U.S. Government.